Search PubMed⌕ Search

Biomedical subjects

R T Adamian

Publications and source records attributed to R T Adamian.

At least 19 recordsLinked to original sources
PubMed2005

[Blood-type and rhesus distribution in Armenian women with endometrial carcinoma].

ABO blood-type and rhesus distribution were studied in 548 Armenian women with endometrial carcinoma according to Rh-Hr system. The control group included 33,413 plus 440 healthy Armenian women with similar blood characteristics. The ratio of individuals with AB (IV) Rh (-) blood was found to be significantly higher (p < 0.05) as compared to controls. It is suggested that these findings should be taken into account when forming high-risk groups of Armenian patients with endometrial carcinoma.

Adult↗
PubMed2004

[Use of fibrin glue for covering microsurgical autotransplants with free split skin].

An experimental study on 90 Wistar rats has been carried out. A split skin transplant about 2.25 cm(2) in size was taken from the back of the animal with scalpel and fixed on the neck's muscles with: 1) 8 sutures; 2) pressure dressing of "Pelot" type; 3) 0.2 ml of "Tissukol" fibrin glue. There were no complications. Complete skin retention was achieved in all the cases. Histological study demonstrated acceleration of reparative processes and decreased inflammation in autotransplant and muscular bed due to improvement of revascularization, a decrease of fibrous transformation of the skin graft and muscular tissue when fibrin glue (to a greater extent) and pressure dressing (to a lesser extent) were used for fixation of skin graft. But it is preferable to use fibrin glue due to acceleration of complete skin retention compared with pressure dressing of "Pelot" type.

Animals↗
PubMed2002

[Diagnostic potential of fiberoptic cervico-hysteroscopy with morphologic examination of biopsied tissues in endometrial and cervical malignancies].

Fibrocervicohysteroscopy (FCHS) is a highly informative method of visual diagnosis of various endometrial and cervical pathologies (benign and malignant polyps, hyperplasia including atypical glandular one) and endometrial carcinoma (including involvement of the cervical canal). The accuracy of FCHS will be further increased if it is used in conjunction with morphological (cytologic and histologic) examination of hysterobioptates.

Biopsy↗
PubMed2001

[Therapy of atypical hyperplasia and adenocarcinoma of the endometrium with the combination of progestins and anticoagulants].

The data on clinical trials of newly-developed hormonotherapy of atypical hyperplasia (AH) and cervical adenocarcinoma (CAC) are presented. The study included 34 patients with histologically--confirmed AH and 86--CAC (stage I-II and III-IV). All patients were given preoperative "shock therapy" with a combination of progestins and anticoagulants: 500 mg, i.v., 10 days--(AH) and well-differentiated cell CAC; 20 days--moderately- and poorly-differentiated cell CAC. Total dose was 5 g and 10 g, respectively. Fibrolysin, pelentan and aspirin (antiaggregant of thrombocytes) were used as anticoagulants. For comparison, identical numbers of AH and CAC patients received similar preoperative progestin therapy without anticoagulants. The study was randomized. Hormonal pathomorphosis in tumor was identified after surgery and relevant characteristics of bioptical and resected material were compared. It was found that hormonotherapy used in conjunction with anticoagulants reinforced significantly all features of hormonal pathomorphosism both in AH and CAC stage I-II while, in well-differentiated cell adenocarcinoma, the difference from control was significant (p < 0.05).

17 alpha-Hydroxyprogesterone Caproate↗
PubMed1999

[The effect of live tularemia vaccination on the short- and long-term results of combined therapy of patients with endometrial cancer].

A randomized investigation of the immediate (wound healing) and end-results (relapse and metastasis frequency, recurrence-free period, 2-, 3- or 5-year survival, lethality rate and mean lifespan) of combined (surgery + distant gamma-therapy) treatment of two groups of patients with endometrial carcinoma was carried out. The study group was operated on days 15-20 after immunization with tularemia live vaccine (TLV) while the controls were had no preliminary immunization. It was shown that all indices of the immediate and end-results of treatment were significantly better in the study group for all stages. It is concluded that TLV immunization given 15-20 days before surgery is followed by a lower frequency of postoperative complications and better end-results.

Bacterial Vaccines↗
PubMed1999

[The effect of tularemia live vaccine on contrasuppression of lymphocytes in patients with cancer of the corpus uteri during combined therapy and long term].

A significant decrease in the percentage of women showing contrasuppression of blood lymphocytes, as compared with control, was identified (p < 0.1); it was particularly low at terminal stages (III-IV). Surgery and subsequent radiotherapy were followed by further inhibition, particularly in terminally-ill patients. Two or three years after treatment, the numbers of patients in all stage groups showing contrasuppression increased, reaching the initial, i.e. lower than normal, levels. However, contrasuppression indices rose to normal in patients immunized with tularemia live vaccine (p > 0.05). This effect was observed in patients of all stage groups, immunized prior to treatment, on days 15-20 after immunization. Normal levels of contrasuppression were maintained during treatment and 2-3 years on. Both contrasuppression level and stage of tumor may serve as a criterion of gravity of disease and prognosis.

Bacterial Vaccines↗
PubMed1998

[Effect of live tularemia vaccine on some parameters of immune and non-specific antitumor resistance in endometrial cancer patients during combined therapy and later].

The levels of T-system lymphocytes, macrophageal transformation of mononuclears and phagocytic activity of blood neutrophils were assayed in 194 patients with endometrial tumors, stage I-IV, (FIGO, 1988), 10-15 days after surgery, a subsequent course of telegammatherapy and 2-3 years after treatment. Ninety-seven patients of the study group were challenged by immunization with a live tularemia vaccine (LTV) 15-20 days before surgery, while the same number of controls were not. The study was randomized. Pre-operative LTV immunization showed an immunoprotective effect at all stages of combined treatment (surgery + telegammatherapy) given for endometrial carcinoma. Moreover, all said indices came back to normal in the study group 2-3 years after treatment. After surgery alone (standard uterine extirpation or with adnexa), controls with malignancies at the same stages revealed a significant decrease in the indices which fell further after radiotherapy. In the latter group, the indices came back to initial values which were below the norm.

Bacterial Vaccines↗
PubMed1997

[Immediate and long-term results of combined therapy of patients with endometrial neoplasms depending on the effect of counter-suppression of blood lymphocytes].

The short-term (wound healing) and end-results (relapse and metastasis frequency, duration of relapse-free survival and 2-, 3- and 5-year survival) of combined treatment (surgery + gamma therapy) of 97 patients with endometrial carcinoma (stage I-II and stage III-IV) (FIGO, 1988) versus the effect of preoperative counter-suppression of blood lymphocytes were investigated. Both short-term and end-results appeared to be much better in patients showing the counter-suppression effect; they were much worse in patients who revealed the effect prior to combined therapy, and still worse--in cases of inverse effect involving enhanced suppression. It is suggested that the effect of blood lymphocyte counter-suppression before combined treatment is a factor of favorable prognosis in patients with endometrial carcinoma.

Combined Modality Therapy↗
PubMed1997

[Adjuvant immunotherapy for patients with cancer of corpus uteri].

A randomized study was carried out of the efficacy of a new procedure of adjuvant immunotherapy for cancer of corpus uteri in conjunction with anticoagulant treatment. Ninety-seven patients (76-stage I-II and 21-stage III-IV) were inoculated tularemia booster (TB) and received fibrinolysin, pelentan and aspirin 15-20 days before combined treatment including uterine extirpation or extirpation with adnexa followed by telegammatherapy. Two groups of identical numbers of patients with an identical distribution of tumor progression stage were used as controls. No vaccination was carried out in one of them while TB inoculation was performed without anticoagulants in the other. A higher effectiveness of immunostimulation accompanied by anticoagulant administration was registered on the basis of the short-term (wound healing) and end results (relapse and metastasis frequency, duration of relapse-free survival and 2-, 3- and 5-year survival).

Anticoagulants↗
PubMed1996

[Evaluation of immunotherapy in breast cancer (stage III-IV) and in cancer of the corpus uteri (stage I-III)].

A new clinically-tested procedure of adjuvant immunotherapy carried out in conjunction with anticoagulant treatment is discussed. Application of said method has significantly improved the short-term and end results of treatment of inoperable cases of breast cancer, stage III-IV, receiving chemotherapy and patients with cancer of corpus uteri, stage I-III, receiving combined therapy plus radiation.

Anticoagulants↗
PubMed1995

[The effect of tularemia vaccine on some parameters of immune and non-specific anti-tumor resistance in patients with endometrial tumors].

On days 15-20 after immunization of patients suffering from endometrial tumors with tularemia live vaccine, a significant increase was registered in T-cell population of the immune system, macrophagal transformation of mononuclears and phagocyticity of blood neutrophiles which are generally reduced in stages III-IV. The study group included cases of all tumor stages. Said indices reached normal levels in stage I-II only.

Bacterial Vaccines↗
PubMed1991

[Clinico-morphological signs of hormone-producing ovarian tumors].

Apparent signs of hormonal activity were observed in 65.3% of patients with hormone-producing ovarian tumors of different histology. Feminization was evident in 69.1% of cases of granulosa-stromal cell tumors: it was most often seen in patients with mixed theca-granulosa cell tumors (86.2%) but was least frequent in those with Brenner's tumor (22.2%). The occurrence of proliferative lesions of the uterus such as hyperplasia of the endometrium, cervical canal polyps and uterine myoma (81.8%) was higher in patients with granulosa-stromal cell tumors, too, the highest rate being observed for cases of mixed theca-granulosa cell tumors (93.1%) whereas the lowest--for patients with Brenner's tumor (27.8%). Various clinical signs of masculinization were most often seen in cases of androblastoma (79.2%) whereas the proliferative disorders in that group were rare (12.5%). As a result, the authors placed mixed theca-granulosa cell, theca cell, granulosa cell tumors and Brenner's tumor in the order of decreasing feminizing activity. In the granulosa-stromal cell tumor subgroup, masculinization was most often observed in granulosa cell tumor patients (12.1%).

Brenner Tumor↗
PubMed1991

[The prognostic factors in patients with malignant granulosa-theca cell tumors of the ovaries].

The extent of tumor, as revealed by surgery in 113 primary patients with malignant granulosa-stromal cell tumors of the ovaries (granulosa cell--77, theca cell--17 and mixed theca-granulosa cell tumors--19 patients), was analysed versus duration of disease, laterality of tumor and patient age. Factors which were significantly or as a marked tendency associated with stage III and IV of disease and thus suggested poor prognosis were identified.

Age Factors↗